BioPharma Resources

Drug Trial Radar · NCT07181109

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 11,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

11,000

Planned (sponsor's estimate)

Start

Sep 6, 2025

Primary completion

Sep 23, 2030

Study completion Sep 23, 2030

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
Collaborators
Hoffmann-La Roche
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Conditions

  • High Risk Cardiovascular Disease
  • Hypertension
  • High Cardiovascular Risk

Interventions

  • ZilebesiranDrug

    Zilebesiran will be administered SC

  • PlaceboDrug

    Placebo will be administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit)Time frame: Up to approximately 5 years

Locations

1,226 sites in 35 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Birmingham, Alabama · Recruiting

  • Clinical Trial Site

    Birmingham, Alabama · Recruiting

  • Clinical Trial Site

    Fairhope, Alabama · Recruiting

  • Clinical Trial Site

    Foley, Alabama · Recruiting

  • Clinical Trial Site

    Huntsville, Alabama · Recruiting

  • Clinical Trial Site

    Huntsville, Alabama · Recruiting

  • Clinical Trial Site

    Sheffield, Alabama · Recruiting

  • Clinical Trial Site

    Chandler, Arizona · Recruiting

  • Clinical Trial Site

    Gilbert, Arizona · Recruiting

  • Clinical Trial Site

    Glendale, Arizona · Completed

  • Clinical Trial Site

    Mesa, Arizona · Recruiting

  • Clinical Trial Site

    Phoenix, Arizona · Recruiting

  • Clinical Trial Site

    Phoenix, Arizona · Recruiting

  • Clinical Trial Site

    Sun City, Arizona · Recruiting

  • Clinical Trial Site

    Sun City West, Arizona · Recruiting

  • Clinical Trial Site

    Tempe, Arizona · Recruiting

  • Clinical Trial Site

    Tucson, Arizona · Recruiting

  • Clinical Trial Site

    Tucson, Arizona · Recruiting

  • Clinical Trial Site

    Yuma, Arizona · Recruiting

  • Clinical Trial Site

    Little Rock, Arkansas · Recruiting

  • Clinical Trial Site

    Little Rock, Arkansas · Recruiting

  • Clinical Trial Site

    Beverly Hills, California · Recruiting

  • Clinical Trial Site

    Chula Vista, California · Recruiting

  • Clinical Trial Site

    Covina, California · Recruiting

  • Clinical Trial Site

    Escondido, California · Recruiting

  • Clinical Trial Site

    Glendale, California · Recruiting

  • Clinical Trial Site

    Huntington Beach, California · Recruiting

  • Clinical Trial Site

    La Jolla, California · Recruiting

  • Clinical Trial Site

    Lancaster, California · Recruiting

  • Clinical Trial Site

    Long Beach, California · Recruiting

  • Clinical Trial Site

    Lynwood, California · Recruiting

  • Clinical Trial Site

    Newhall, California · Recruiting

  • Clinical Trial Site

    Northridge, California · Recruiting

  • Clinical Trial Site

    Pasadena, California · Recruiting

  • Clinical Trial Site

    San Diego, California · Recruiting

  • Clinical Trial Site

    San Dimas, California · Recruiting

  • Clinical Trial Site

    San Ramon, California · Recruiting

  • Clinical Trial Site

    Stockton, California · Recruiting

  • Clinical Trial Site

    Tarzana, California · Recruiting

  • Clinical Trial Site

    Toluca Lake, California · Recruiting

Showing 40 of 1,226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.